These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20820775)

  • 1. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers.
    Geller MA; Cooley S; Argenta PA; Downs LS; Carson LF; Judson PL; Ghebre R; Weigel B; Panoskaltsis-Mortari A; Curtsinger J; Miller JS
    Cancer Immunol Immunother; 2010 Dec; 59(12):1877-1884. PubMed ID: 20820775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies.
    Weigel BJ; Cooley S; DeFor T; Weisdorf DJ; Panoskaltsis-Mortari A; Chen W; Blazar BR; Miller JS
    Am J Hematol; 2012 Oct; 87(10):953-6. PubMed ID: 22718533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.
    Dudek AZ; Yunis C; Harrison LI; Kumar S; Hawkinson R; Cooley S; Vasilakos JP; Gorski KS; Miller JS
    Clin Cancer Res; 2007 Dec; 13(23):7119-25. PubMed ID: 18056192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma.
    Dummer R; Hauschild A; Becker JC; Grob JJ; Schadendorf D; Tebbs V; Skalsky J; Kaehler KC; Moosbauer S; Clark R; Meng TC; Urosevic M
    Clin Cancer Res; 2008 Feb; 14(3):856-64. PubMed ID: 18245549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
    O'Malley DM; Azodi M; Makkenchery A; Tangir J; McAlpine J; Kelly M; Schwartz P; Rutherford T
    Gynecol Oncol; 2005 Aug; 98(2):242-8. PubMed ID: 15992916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers.
    Morris R; Alvarez RD; Andrews S; Malone J; Bryant C; Heilbrun LK; Smith D; Schimp V; Munkarah A
    Gynecol Oncol; 2008 Jun; 109(3):346-52. PubMed ID: 18410954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans.
    Harrison LI; Astry C; Kumar S; Yunis C
    J Clin Pharmacol; 2007 Aug; 47(8):962-9. PubMed ID: 17660481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.
    Inglefield JR; Dumitru CD; Alkan SS; Gibson SJ; Lipson KE; Tomai MA; Larson CJ; Vasilakos JP
    J Interferon Cytokine Res; 2008 Apr; 28(4):253-63. PubMed ID: 18439103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous pharmacodynamics of a toll-like receptor 7 agonist, 852A, in humans.
    Astry C; Birmachu W; Harrison LI; Meng TC
    J Clin Pharmacol; 2008 Jun; 48(6):755-62. PubMed ID: 18401016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of the anti-tumor effects of imidazoquinoline immune response modifiers by cyclophosphamide.
    Dumitru CD; Antonysamy MA; Tomai MA; Lipson KE
    Cancer Biol Ther; 2010 Jul; 10(2):155-65. PubMed ID: 20519933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience.
    Hu CF; Ou YC; Fu HC; Chang Chien CC; Tsai CC; Wu CH; Lin H
    Taiwan J Obstet Gynecol; 2015 Feb; 54(1):43-7. PubMed ID: 25675918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.
    Rowinsky EK; Noe DA; Grochow LB; Sartorious SE; Bowling MK; Chen TL; Lubejko BG; Kaufmann SH; Donehower RC
    J Clin Oncol; 1995 Aug; 13(8):1975-84. PubMed ID: 7636538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma.
    Kurbacher CM; Kurbacher JA; Cramer EM; Rhiem K; Mallman PK; Reichelt R; Reinhold U; Stier U; Cree IA
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 2):23-6. PubMed ID: 15934497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory therapy in refractory/recurrent ovarian cancer.
    Chen CY; Lai CH; Yang LY; Tang YH; Chou HH; Chang CJ; Lin CT
    Taiwan J Obstet Gynecol; 2015 Apr; 54(2):143-9. PubMed ID: 25951718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer.
    Estes JM; Leath CA; Williams S; Modiano MR; Sawyer M; Cohn D; Straughn JM; Barnes MN; Alvarez RD
    Gynecol Oncol; 2006 Aug; 102(2):338-42. PubMed ID: 16487997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer.
    Bhoola SM; Coleman RL; Herzog T; Morris R; Bryant C; Estes JM; Alvarez RD
    Gynecol Oncol; 2004 Dec; 95(3):564-9. PubMed ID: 15581964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of weekly docetaxel for patients with advanced or recurrent cancer of the cervix.
    Pearl ML; Johnston CM; McMeekin DS
    Gynecol Obstet Invest; 2007; 64(4):193-8. PubMed ID: 17664880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.
    Diamond JR; Goff B; Forster MD; Bendell JC; Britten CD; Gordon MS; Gabra H; Waterhouse DM; Poole M; Ross Camidge D; Hamilton E; Moore KM
    Invest New Drugs; 2017 Oct; 35(5):627-633. PubMed ID: 28283779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma.
    Piura B; Meirovitz M
    Eur J Gynaecol Oncol; 2005; 26(4):386-90. PubMed ID: 16122184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.